New therapeutic targets and drugs in non-Hodgkin's lymphoma

Current Opinion in Hematology

Volumn 18, Issue 4, 2011, Pages 280-287

  Sawas, Ahmed ^a   Diefenbach, Catherine ^a   O'Connor, Owen A ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; histone deacetylase inhibitors; Hodgkin's lymphoma; new drugs; non Hodgkin's lymphoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 HYDROXYCYCLOPHOSPHAMIDE; BELINOSTAT; BENDAMUSTINE; BORTEZOMIB; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CAL 101; CARFILZOMIB; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; GEMCITABINE; ISOSORBIDE; LENALIDOMIDE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PACLITAXEL; PCI 32765; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; ROMIDEPSIN; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ARTHRITIS FLARE; ASTHENIA; ATAXIA; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPHORIA; FATIGUE; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; ILEUS; KIDNEY CANCER; KIDNEY GRAFT REJECTION; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; LYMPHOCYTOMA; LYMPHOCYTOPENIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; SOMNOLENCE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASE;

EID: 79958789629     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328347786d     Document Type: Review

References (62)

1. Zelenetz AD, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010; 8:288-334.
2. Rogers BB. Overview of non-Hodgkin's lymphoma. Semin Oncol Nurs 2006; 22:67-72. (Pubitemid 43729581)
3. Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130:691-699.
4. Recher, Coiffier B, Haioun C, et al. A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B [abstract]. ASH Annual Meeting Abstracts, 2010; 116:109.
5. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732. (Pubitemid 41742196)
7. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma [abstract]. ASH Annual Meeting Abstracts 2010; 116:1777.
8. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. ASH Annual Meeting Abstracts, 2010; 116:55.
9. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/ refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010; 16:1033-1041.
10. Carlo-Stella C, Guidetti A, Viviani S, et al. Clinical activity and safety of the combined therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory lymphomas: preliminary results of a phase II trial [abstract]. ASH Annual Meeting Abstracts 2010; 116:2861.
11. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in nonmantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago Phase II Consortium. J Clin Oncol 2010; 28:4740-4746.
12. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822-3829.
13. Witzig TE, Reeder CB, Laplant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25:341-347.
14. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85:320-324.
15. Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008; 143:355-360.
16. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted highaffinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11:1149-1159.
17. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113:299-305.
18. Castro JE, Olivier LJ, Robier AA, et al. A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. ASH Annual Meeting Abstracts 2006; 108:2838.
19. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory Bcell malignancies: results from a phase I study [abstract]. ASH Annual Meeting Abstracts 2010; 116:964.
20. Burger JA, O'Brien S, Fowler N, et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies [abstract]. ASH Annual Meeting Abstracts 2010; 116:57.
21. Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29:1198-1203.
22. Piekarz RL, Frye R, Prince HM, et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011 [Epub ahead of print].
23. Pohlman B, Advani R, DuvicM, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]. ASH Annual Meeting Abstracts 2009; 114: 920.
24. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7:606-619. (Pubitemid 44100518)
25. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009; 36 (Suppl 3):S3-S17.
26. Osaki M, Kase S, Adachi K, et al. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 2004; 130: 8-14. (Pubitemid 38161242)
27. Dou AX, Wang X. Cyclic adenosine monophosphate signal pathway in targeted therapy of lymphoma. Chin Med J (Engl) 2010; 123:95-99.
28. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals [abstract]. Blood 2010; 116:2078-2088.
29. Flinn IW, Schreeder MT, Wagner-Johnston N, et al. A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies [abstract]. ASH Annual Meeting Abstracts 2010; 116:2832.
30. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma 2009; 50:1916-1930.
31. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113:508-514.
32. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-5356. (Pubitemid 46206988)
33. O'Connor OA, Popplewell L, Winter JN, et al. PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib [abstract]. ASH Annual Meeting Abstracts 2010; 116:3963.
34. Chiang CT, Yeh PY, Gao M, et al. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Lett 2010; 298:195-203.
35. Vu C, Fruman DA. Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res 2010; 16:5374-5380.
36. Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102:972-980. (Pubitemid 36917792)
37. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90:244-251. (Pubitemid 27276568)
38. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copynumber alteration across human cancers. Nature 2010; 463:899-905.
39. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101:4279-4284. (Pubitemid 36857789)
40. Stolz C, Hess G, Hahnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008; 112:3312-3321.
41. Wobser M, Voigt H, Eggert AO, et al. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer 2007; 96:1540-1543. (Pubitemid 46762957)
42. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15:1126-1132.
43. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18:1812-1823. (Pubitemid 30261918)
44. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25:1114-1120. (Pubitemid 46596764)
45. O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27:5208-5212.
46. Lin TS. New agents in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2010; 5:29-34.
47. Kahl B, Roberts AW, Seymour JF, et al. Navitoclax (ABT-263) plus rituximab: interim results of a phase 1 study in patients with CD20-positive lymphoid malignancies [abstract]. ASH Annual Meeting Abstracts 2010; 116:3943.
48. Kipps TJ, Wierda WG, Jones JA, et al. Navitoclax (ABT-263) plus fludarabine/ cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR): a phase 1 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) [abstract]. ASH Annual Meeting Abstracts 2010; 116:2455.
49. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115:3304-3313.
50. Leber B, Geng F, Kale J, Andrews DW. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med 2010; 12:e28.
51. Goy A, Ford P, Feldman T, et al. A phase 1 trial of the Pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma [abstract]. ASH Annual Meeting Abstracts 2007; 110:2569.
52. Koh GS, Jiang N, Dong DF, et al. BH3-mimetics, ABT-737 and obatoclax, work synergistically to induce cell death in leukemic cell lines [abstract]. ASH Annual Meeting Abstracts 2010; 116:1850.
53. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008; 111:5350-5358.
54. Kumar S, Kline M, Kimlinger T, et al. AT-101, a small molecule inhibitor of Bcl-2 family proteins, has significant in vitro activity in multiple myeloma [abstract]. ASH Annual Meeting Abstracts 2005; 106:1581.
55. Castro JE, Loria OJ, Aguillon RA, et al. A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens [abstract]. ASH Annual Meeting Abstracts 2007; 110:3119.
56. Flemming A. Target discovery: blocking BTK in B-cell disorders. Nat Rev Drug Discov 2010; 9:681.
57. Pollyea, D.A., et al. A phase I dose escalation study of the Btk inhibitor PCI-32765. in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay [abstract]. ASH Annual Meeting Abstracts 2009; 114:3713.
58. Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010; 148:256-267.
59. Sandor V, Senderowicz A, Mertins S, et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83:817-825.
60. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009; 15:3918-3926.
61. Kirschbaum M, Popplewell L, Delioukina ML, et al. A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) plus rituximab in newly diagnosed, relapsed or refractory indolent non-Hodgkin's lymphoma [abstract]. ASH Annual Meeting Abstracts 2010; 116:3957.
62. Zain JM, Foss FM, de Bono JS, et al. Interim results of a phase 1 trial of an oral histone deacetylase inhibitor belinostat in patients with lymphoid malignancies [abstract]. ASH Annual Meeting Abstracts 2010; 116:1787.